Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) (HEP001)

Cellaion

Status and phase: Completed; Phase 2; Phase 1

Conditions: Urea Cycle Disorders; Crigler Najjar Syndrome

Treatments: Biological: HepaStem

Study type: Interventional

Funder types: Industry

Identifiers

NCT01765283

HEP001

Details and patient eligibility

About

The purpose of this study is to assess the safety and to appraise the efficacy of one cycle of Hepastem (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC) infusions in paediatric patients suffering from CN or UCD.

The study duration: 12 months starting from the day of treatment: 6 months active surveillance and 6 months observation post-infusion.

Enrollment: 20 patients

Sex: All

Ages: Under 17 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

GENERAL:

1. Subject shows patency of the portal vein and branches, with normal flow velocity in the main portal vein as confirmed by Doppler ultrasound and accessibility of the portal vein, or respectively, accessibility of the umbilical vein.
2. Subject (if capable of signing) and parents or legal representative have provided a written informed assent/consent.
3. Female subjects of childbearing potential need to have a negative pregnancy test and must agree to use an acceptable method of contraception throughout the study.

MAIN INCLUSION CRITERIA

Crigler-Najjar Syndrome specific:

• Patient presents with Crigler-Najjar syndrome type 1.
• Patient presents with Crigler-Najjar syndrome type 2, poorly controlled under phenobarbital treatment, or experiencing serious impairment in quality of life.

Diagnosis must be confirmed by genetic mutation analysis if not available.

Urea Cycle Disorders specific:

• Diagnosis of one of the urea cycle disorders of which the disease is of such severity to warrant liver transplantation or alternatives despite full conservative therapy,
• subject experiencing serious impairment in quality of life despite full conservative therapy.

MAIN EXCLUSION CRITERIA

• The subject is 18 years or older at time of screening.
• The subject presents acute liver failure, clinical or radiological evidence of liver fibrosis or cirrhosis, presents or has a history of hepatic or extrahepatic malignancy
• The patient has a non-corrected cardiac malformation, has a known medical or family history of coagulopathy, had or has a renal insufficiency treated by dialysis.
• The subject requires valproate therapy.
• The subject has a thrombosis of the portal vein or persisting impairment of anterograde portal blood flow.
• The subject has a porto systemic shunt or fistula assessed by Doppler US.
• Patients with disease of such severity that liver transplantation is an absolute indication.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 3 patient groups

Hepastem Low dose

Experimental group

Description:

12.5x106cells/kg

Treatment:

Biological: HepaStem

Hepastem Intermediate dose

Experimental group

Description:

50x106cells/kg

Treatment:

Biological: HepaStem

Hepastem High dose

Experimental group

Description:

200x106cells/kg

Treatment:

Biological: HepaStem